Tag: industries

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.

New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Snow Rothschild Acquisition Corp. (NASDAQ: ISNRU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. Each unit issued in the offering consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust acting as trustee.  The Company’s units are expected to be listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ISNRU” and are expected to begin trading on June 9, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ISNR” and “ISNRW,” respectively. The closing of the offering is anticipated to take place on or about June 10, 2026, subject to customary closing conditions.

New York, NY, June 08, 2026 (GLOBE NEWSWIRE) -- FutureCorp Space Acquisition 1 (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on June 5, 2026 on The New York Stock Exchange (“NYSE”) under the ticker symbol “FTRAU.” Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share, subject to certain adjustment. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols “FTRA” and “FTRAW,” respectively. Of the proceeds received from the consummation of the initial public offering (including the exercise of the over-allotment option) and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in trust.